• Boustead Securities

Boustead Securities Raises $61.9M For Client Molecular Data Inc.



Boustead Securities, LLC., (“Boustead”) served as Sole U.S. Managing Underwriter for the US$61.9 million Nasdaq IPO of its client, Molecular Data Inc. (“Molecular Data” or the “Company”) (Nasdaq: MKD), a leading technology-driven platform in China’s chemical industry. On December 27, 2019 MKD priced its initial public offering of 11,500,000 American depositary shares (“ADS”) at a price to the public of US$5.38 per ADS, and commenced trading on Nasdaq on December 30, 2019.


AMTD Global Markets Limited, Fosun Hani Securities Limited and Boustead Securities, LLC acted as the representatives of the underwriters jointly.


A registration statement related to these securities has been filed with, and declared effective by, the United States Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Past performance is not indicative of future results. There is no guarantee that any specific outcome will be achieved. Investments may be speculative, illiquid and there is a risk of total loss.


This offering is being made only by means of a prospectus forming part of the effective registration statement. A copy of the final prospectus relating to the offering may be obtained, when available, by contacting the following underwriters: (1) AMTD Global Markets Limited, Address: 23/F - 25/F Nexxus Building, 41 Connaught Road Central, Hong Kong, by telephone at +852-3163-3288, or via email: prospectus@amtdgroup.com; (2) Fosun Hani Securities Limited, Address: Suite 2101 – 2105, 21/F, Champion Tower, 3 Garden Road, Central, Hong Kong, by telephone at +852-2869-1318, or by emailing: project.magic@fosunhani.com; (3) Boustead Securities, LLC, Address: 6 Venture, Suite 395, Irvine, CA 92618, USA, by telephone at +1-949-502-4408 or by emailing offerings@boustead1828.com.



About Molecular Data Inc

Molecular Data Inc. is a leading technology-driven platform in China’s chemical industry, connecting participants along the chemical value chain through integrated solutions. The Company delivers e-commerce solutions, financial solutions, warehousing and logistics solutions, and SaaS suite that are intended to solve pain points for participants in the traditional chemical industry. Built upon a comprehensive knowledge engine and artificial intelligence ("AI") capabilities, the Company’s e-commerce solutions are mainly offered through its online platform, consisting of molbase.com, molbase.cn, Moku Data Weixin account, Chemical Community App and other ancillary platforms.


For investor and media inquiries, please contact:


In China:

Molecular Data Inc.

Investor Relations

Tel: +86-400-6021-666

E-mail: Investor@molbase.com


The Piacente Group, Inc.

Emilie Wu

Tel: +86-21-6039-8363

E-mail: molbase@tpg-ir.com


In the United States:

The Piacente Group, Inc.

Brandi Piacente

Tel: +1-212-481-2050

E-mail: molbase@tpg-ir.com


Source: Molbase



About Boustead Securities, LLC


Boustead Securities, LLC (“Boustead”), a member of FINRA and SIPC, is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com.



Forward Looking Statements


This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.

0 views

6 Venture, Suite 395

Irvine, CA 92618 USA

Locate Us

+1.949.502.4408

info@boustead1828.com

  • White LinkedIn Icon
  • White Facebook Icon
For any general inquiries, please fill in the following contact form: